Methylphenidate
Methylphenidate is a central nervous system stimulant1 of the phenidate class. First synthesized in 1944,2 it became one of the most widely prescribed medications for attention deficit hyperactivity disorder (ADHD) and narcolepsy,1 marketed under brands such as Ritalin1 and Concerta3. Outside clinical settings, it is used recreationally4 and as a cognitive enhancer,4 though its stimulant and euphoric effects are generally considered less pronounced than those of amphetamines.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of methylphenidate can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The cognitive effects of methylphenidate can be broken down into several components which progressively intensify proportional to dosage. The general head space of methylphenidate is described by many as one of extreme mental stimulation, increased focus, and powerful euphoria. It contains a large number of typical stimulant cognitive effects. Although negative side effects are usually mild at low to moderate dosages, they become increasingly likely to manifest themselves with higher amounts or extended usage. This particularly holds true during the offset of the experience.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Methylphenidate acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI)5, blocking both the dopamine transporter (DAT) and the norepinephrine transporter (NET) to increase extraneuronal concentrations of these neurotransmitters.5 Its activity is most pronounced at the dopamine transporter, with a lesser degree of norepinephrine reuptake inhibition. Both enantiomers of the racemic mixture display affinity for the serotonin 5-HT1A receptor, though no direct binding to the serotonin transporter has been observed.6 Initial findings also suggested affinity at the 5-HT2B receptor, but a subsequent study found no significant activity at this site.7
Pharmacokinetics
Methylphenidate undergoes extensive first-pass metabolism in the liver, resulting in oral bioavailability of approximately 11 to 52% with considerable individual variation.8 It is rapidly metabolized by the carboxylesterase enzyme CES1A1 via de-esterification to ritalinic acid, which possesses little to no pharmacological activity.98 The d-isomer is substantially more bioavailable than the l-isomer when taken orally and is primarily responsible for the pharmacological effects of the racemic mixture.8 Approximately 97% of the metabolized drug is excreted in urine, with less than 1% appearing unchanged.8 The elimination half-life of immediate-release formulations is approximately 2 to 3 hours.10
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Other dopaminergic stimulants
Harm Potential
Addiction & Dependence
Psychological
ModerateMethylphenidate has moderate liability among addictive drugs, with addiction and psychological dependence occurring primarily when used at high doses or in non-medical contexts. At therapeutic doses, it does not sufficiently activate the reward system to cause addiction; however, its dopamine reuptake inhibition can induce euphoria at higher doses, contributing to abuse potential.114
Physical
LowPhysical dependence and withdrawal are mainly reported with high-dose or non-medical use and are uncommon at therapeutic doses.12 Withdrawal symptoms following abrupt discontinuation may include lethargy, apathy, depression, and paranoia, but these are not life-threatening.
Toxicity
Acute cardiovascular effects including elevated heart rate, blood pressure changes, and palpitations occur during use; these are typically mild at therapeutic doses.13 FDA studies found no association between medical use and serious cardiovascular events such as sudden death, heart attack, or stroke.1415 Higher doses and overdose may cause cardiac arrhythmias.
Liver toxicity from methylphenidate is extremely rare; limited evidence suggests the risk may increase when combined with β-adrenergic agonists.16
Rhabdomyolysis has been reported primarily in severe overdose situations or with large doses that induce hyperthermia and excessive muscular activity.17
Intravenous injection of crushed tablet preparations can cause severe toxic reactions including abscess formation, tissue necrosis, and pulmonary or cerebral embolism due to insoluble binders and fillers.18
Long-term treatment in children has been associated with mild reductions in height, estimated at approximately 1 cm or less per year during the first three years, with a total decrease of about 3 cm over 10 years of continuous treatment.19
Psychosis Risk
Methylphenidate can worsen psychosis in people who are already psychotic; in very rare cases, it has been associated with the emergence of new psychotic symptoms.20 Visual hallucinations are very rarely reported. Overdose may trigger hallucinations and delirium. Should be used with extreme caution in people with bipolar disorder due to potential induction of mania or hypomania.21
Seizure Risk
Seizures and convulsions are associated with abusive use, higher doses, and severe overdose rather than typical therapeutic use.22 Convulsions in overdose may be followed by coma.
History & Culture
Discovery and Synthesis
Methylphenidate was first synthesized in 1944 by Swiss chemist Leandro Panizzon while working for the pharmaceutical company CIBA (now Novartis).23 Panizzon named the compound after his wife Marguerite, nicknamed "Rita," who became the first person to…
Legality
By Country
United States Virgin Islands
References
Source Pages
Citations
- (n.d.). RITALIN- methylphenidate hydrochloride tablet. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a123
- (n.d.). Methylphenidate. American Chemical Society. https://www.acs.org/molecule-of-the-week/archive/m/methylphenidate.html1
- (n.d.). CONCERTA- methylphenidate hydrochloride tablet, extended release. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd1
- (n.d.). Methylphenidate - StatPearls. NCBI Bookshelf / StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK482451/1234
- (n.d.). | 2250 |- | [[IC50|IC<sub>50</sub>]] ({{abbr|nM|nanomolar}}) | 20 | 23 | 1600 |- | rowspan="2" | [[Norepinephrine transporter|NET]] | K<sub>i</sub> (nM) | 788 | 206 | >10000 |- | I. https://doi.org/10.1007/s40120-022-00392-212
- (December 2006). A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. Journal of Child and Adolescent Psychopharmacology, 16(6), 687–698. https://doi.org/10.1089/cap.2006.16.687123
- (February 2009). The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor. Die Pharmazie, 64(2), 123–125. https://pubmed.ncbi.nlm.nih.gov/19322953/12
- (15 June 2021). Daytrana- methylphenidate patch. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c312c31-3198-4775-91ab-294e0b4b9e7f1234567
- (August 2004). Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. The Journal of Pharmacology and Experimental Therapeutics, 310(2), 469–476. https://doi.org/10.1124/jpet.104.0671161
- (December 1999). Pharmacokinetics and clinical effectiveness of methylphenidate. Clinical Pharmacokinetics, 37(6), 457–470. https://doi.org/10.2165/00003088-199937060-000021
- (February 2005). Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Current Opinion in Pharmacology, 5(1), 87–93. https://doi.org/10.1016/j.coph.2004.10.0011
- (2025-06-03). Medical management of ADHD in adults: part 2. Drug and Therapeutics Bulletin, 63(6), 85–93. https://doi.org/10.1136/dtb.2025.0000191
- (August 2018). The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. International Journal of Environmental Research and Public Health, 15(8), 1789. https://doi.org/10.3390/ijerph150817891
- (20 December 2011). FDA drug safety communication: Safety review update of medications used to treat attention-deficit / hyperactivity disorder (ADHD) in children and young adults. U.S. Food and Drug Administration (FDA). https://doi.org/10.1056/nejmoa11102121
- (November 2022). Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA Network Open, 5(11), e2243597. https://doi.org/10.1001/jamanetworkopen.2022.435971
- (1997). Adrenergic modulation of hepatotoxicity. Drug Metabolism Reviews, 29(1–2), 329–353. https://doi.org/10.3109/036025397090375871
- (n.d.). Methylphenidate hydrochloride (PIM 344). INCHEM. http://www.inchem.org/documents/pims/pharm/pim344.htm1
- (2011). Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Medical Weekly, 141(3940), w13267. https://doi.org/10.4414/smw.2011.132671
- (August 2005). Growth on stimulant medication; clarifying the confusion: a review. Archives of Disease in Childhood, 90(8), 801–806. https://doi.org/10.1136/adc.2004.0569521
- (July 2010). Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clinical Neuropharmacology, 33(4), 204–206. https://doi.org/10.1097/wnf.0b013e3181e291741
- (2025). Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacology Bulletin, 41(4), 37–47. https://doi.org/10.64719/pb.41041
- (July 2013). Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management. CNS Drugs, 27(7), 531–543. https://doi.org/10.1007/s40263-013-0084-81
- (n.d.). Methylphenidate (Ritalin). Chemistry World. https://www.chemistryworld.com/podcasts/methylphenidate-ritalin/3010477.article1234
- (2016). From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate. Current Neuropharmacology, 14(1), 17–27. https://doi.org/10.2174/1570159x1366615040722590212
- (n.d.). Bradley's Benzedrine Studies on Children with Behavioral Disorders. Journal of Attention Disorders. https://pmc.ncbi.nlm.nih.gov/articles/PMC3064242/1
- (December 1996). Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics, 98(6), 1084–1088. https://pubmed.ncbi.nlm.nih.gov/8951257/1
- (n.d.). Top 300 of 2023. ClinCalc. https://clincalc.com/DrugStats/Top300Drugs.aspx1
- (n.d.). Methylphenidate Drug Usage Statistics, United States, 2014 - 2023. ClinCalc. https://clincalc.com/DrugStats/Drugs/Methylphenidate1
- (n.d.). Portaria SVS/MS No. 344/1998, List A3. antigo.anvisa.gov.br. https://antigo.anvisa.gov.br/documents/10181/2718376/PRT_SVS_344_1998_COMP.pdf1
- (n.d.). Portaria SVS/MS No. 344/1998, List A3. gov.br. https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias1
- (n.d.). Supreme Decree No. 405/1983, Regulation of Psychotropic Products. bcn.cl. https://www.bcn.cl/leychile/Navegar?idNorma=130661
- (n.d.). Methylphenidate - referral | European Medicines Agency. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate12
- (n.d.). Directive 2001/83/EC Article 31 referral. eur-lex.europa.eu. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32001L00831
- (2026). Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study. The Lancet Regional Health - Europe / PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12882648/1
- (n.d.). Betäubungsmittelgesetz, Anlage III. gesetze-im-internet.de. https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html1
- (n.d.). Drugs and Cosmetics Rules 1945, Schedule X. cdsco.gov.in. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf1
- (n.d.). Misuse of Drugs Regulations 2017, Schedule 2. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/2017/si/173/made/en/print1
- (n.d.). Narcotics and Psychotropics Control Act, psychotropics schedule. ncd.mhlw.go.jp. https://www.ncd.mhlw.go.jp/en/application2.html1
- (n.d.). Narcotics and Psychotropics Control Act, psychotropics schedule. mhlw.go.jp. https://www.mhlw.go.jp/web/t_doc?dataId=81102000&dataType=01
- (n.d.). Misuse of Drugs Act 1975, Schedule 2. legislation.govt.nz. https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436206.html1
- (n.d.). Government Resolution No. 681 of 30 June 1998, List I. pravo.gov.ru. http://pravo.gov.ru/proxy/ips/?docbody=&nd=1020548281
- (n.d.). Misuse of Drugs Act 1973, First Schedule. sso.agc.gov.sg. https://sso.agc.gov.sg/Act/MDA19731
- (n.d.). LVFS 2011:10, list of narcotic drugs. lakemedelsverket.se. https://www.lakemedelsverket.se/sv/lagar-och-regler/foreskrifter/2011-101
- (n.d.). Betäubungsmittelverzeichnisverordnung-EDI, Verzeichnis a. fedlex.admin.ch. https://www.fedlex.admin.ch/eli/cc/2011/363/de1
- (n.d.). Controlled Drugs Act, Schedule 3 controlled-drug list. mohw.gov.tw. https://www.mohw.gov.tw/dl-92684-89cddf4d-8d44-49d0-997f-9bbb32e2273f.html1
- (n.d.). Controlled Drugs Act, Schedule 3 controlled-drug list. mohw.gov.tw. https://www.mohw.gov.tw/cp-16-19079-1.html1
- (n.d.). Federal Decree-Law No. 30 of 2021 on Combating Narcotic Drugs and Psychotropic Substances, Schedule 6. uaelegislation.gov.ae. https://uaelegislation.gov.ae/en/legislations/15401
- (n.d.). Federal Decree-Law No. 30 of 2021 on Combating Narcotic Drugs and Psychotropic Substances, Schedule 6. mohap.gov.ae. https://mohap.gov.ae/documents/20117/1212145/Controlled%2Band%2Bsemi-controlled%2Bmedicines%2Blist%2B-%2B331%2BKB.pdf/b50bbe06-b8c8-0635-60ae-dd9fe1e43b15?t=17391551410121
- (n.d.). Misuse of Drugs Act 1971; Misuse of Drugs Regulations 2001; Misuse of Drugs Regulations (Northern Ireland) 2002. legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
- (n.d.). Misuse of Drugs Act 1971; Misuse of Drugs Regulations 2001; Misuse of Drugs Regulations (Northern Ireland) 2002. legislation.gov.uk. https://www.legislation.gov.uk/uksi/2001/3998/schedule/21
- (n.d.). Misuse of Drugs Act 1971; Misuse of Drugs Regulations 2001; Misuse of Drugs Regulations (Northern Ireland) 2002. legislation.gov.uk. https://www.legislation.gov.uk/nisr/2002/1/schedule/21
- (n.d.). Misuse of Drugs Act 1971; Misuse of Drugs Regulations 2001; Misuse of Drugs Regulations (Northern Ireland) 2002. gov.uk. https://www.gov.uk/government/publications/controlled-drugs-list--2/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation1
- (n.d.). Misuse of Drugs Act 1971; Misuse of Drugs Regulations 2001; Misuse of Drugs Regulations (Northern Ireland) 2002. nhs.uk. https://www.nhs.uk/medicines/methylphenidate-children/about-methylphenidate-for-children/1
- (n.d.). V.I. Code tit. 19, §§ 595, 603. law.justia.com. https://law.justia.com/codes/virgin-islands/2019/title-19/part-iii/chapter-29/subchapter-i/595/1
- (n.d.). V.I. Code tit. 19, §§ 595, 603. law.justia.com. https://law.justia.com/codes/virgin-islands/2019/title-19/part-iii/chapter-29/subchapter-i/603/1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Methylphenidate article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.